IDH3A and central nervous system cancer: Isocitrate dehydrogenase (IDH) mutation status was available for 35/37 patients: 31 patients were IDH wild type, while four patients (two WHO grade II glioma, two WHO grade III glioma) carried a mutant IDH allele.